Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham

Documenti analoghi

• Time‐varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling
  di: Sebastiaan Camiel Goulooze, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin
  di: Byungwook Kim, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)
  di: Oneeb Majid, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data
  di: Stefan Willmann, et al.
  Pubblicazione: (2024)
• Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment
  di: Christopher A. Darlow, et al.
  Pubblicazione: (2024)